| Project/Area Number |
15K20856
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
Pharmacology in pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Saito Masaki 東北大学, 医学系研究科, 助教 (50400271)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 副甲状腺ホルモン受容体 / 4.1Gタンパク質 / Tctex-1 / 骨芽細胞分化 / アデニル酸シクラーゼ / サイクリックAMP / 一次繊毛 / ヘッジホッグシグナル / 骨芽細胞 |
|---|
| Outline of Final Research Achievements |
Parathyroid hormone (PTH) is the only medicine, which promotes osteoblast differentiation and osteogenesis. However, mechanisms of the differentiation and osteogenesis have been unclear. In the present study, I found that 4.1G and Tctex-1, both of which were identified as interacting proteins to PTH receptor, suppressed and increased PTH receptor-mediated Gs/adenylyl cyclase/cyclic AMP (cAMP) signaling pathway, respectively. On the other hand, I also found that 4.1G promoted osteoblast differentiation induced by ascorbic acid/β-glycerophosphate, suggesting that 4.1G regulates osteoblast differentiation by different mechanisms from the suppression of cAMP production.
|
